Trelagliptin Succinate Intermediate CAS 865759-24-6 Purity >98.0% (HPLC)

2-((6-chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile (CAS: 865759-24-6) is used as an intermediate of Trelagliptin Succinate (CAS: 1029877-94-8). Trelagliptin Succinate, developed by Takeda, Japan, launched in March 2015, under the trade name Zafatek, is used to treat type 2 diabetes. Trelagliptin is an ultra-long-acting dipeptidyl peptidase IV(DPP-4) inhibitor by selectively and continuously inhibiting DPP-4 to control blood sugar levels. Trelagliptin is the first weekly hypoglycemic drug on the market, and similar DPP-4 inhibitors on the market need to be taken once a day. Zafatek medication advantages will undoubtedly provide more convenient treatment options for diabetic patients. It is expected to greatly improve the convenience and compliance of patients. on March 26, 2015, Japanese pharmaceutical giant Takeda announced that the new diabetes drug Zafatek was approved by Japan's Ministry of health, labor and welfare (MHLW) for the treatment of type 2 diabetes. The approval marks Zafatek becoming the first weekly oral hypoglycemic drug on the market in the world, and also represents a blockbuster dropped by Takeda in the diabetes market.
Trelagliptin is a once-weekly dipeptidyl peptidase IV (DPP-4) inhibitor that controls blood sugar levels by selectively and continuously inhibiting DPP-4. DPP-4 is an enzyme that can initiate the inactivation of incretin (glucagon-like peptide -1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)), which play an important role in blood glucose regulation. Inhibition of DPP-4 can increase blood sugar level-dependent insulin secretion, thus controlling blood sugar level. Trelagliptin NDA submission is based on efficacy and safety data from several phase III clinical trials conducted in Japanese patients with type 2 diabetes. The efficacy of Trelagliptin has been confirmed in all trials, and it has good safety and tolerability. Trelagliptin Administration once a week can effectively control blood sugar level and is expected to improve patients' medication compliance.